{
  "trial_id": "NCT00222105",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "active symptomatic multiple myeloma without prior chemotherapy",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Durie-Salmon Stage II-III A/B",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Stage I patients with at least 2 of the poor prognostic indicators may be eligible",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Patients with plasma cell leukemia",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Non-secretory multiple myeloma patients are eligible",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Patients between the ages of 18 and 75 years old",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Female Patients of child bearing age (up to age 50) who are not pregnant and agree to use two adequate birth control methods during the study and at least six months after treatment unless patient has undergone hysterectomy or has been in menopause for 2 years",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Patients with Southwest Oncology Group (SWOG) performance status of 3 or better",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients who have received prior lower dose Dexamethasone Therapy (ie. 4 mg QID) as adjunct to radiation therapy for cord compression may be eligible",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "All patients must have a MUGA scan indicating a left ventricular ejection fraction (LVEF) of greater than or equal to 50% within 42 days prior to registration",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Must be able to understand English",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Must be willing and eligible to sign up for the STEPS program",
      "label": "met",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Nursing mothers or women who are pregnant",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Patients with a history of hypersensitivity reaction to doxorubicin or agents in Doxil\u00ae",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients with previous malignancies at other sites except surgically treated nonmelanomatous skin cancers, prostate cancer or superficial cervical cancers, or other cancer from which the patient had been disease free for 5 or more years.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "History of mediastinal radiation for any reason",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "History of receiving prior anthracyclines",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients with uncontrolled medical problems such as diabetes mellitus, cardiac, pulmonary, hepatic, and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Myocardial infarction within 6 months of enrollment in the study.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Major surgery within 4 weeks of enrollment.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has multiple myeloma with recurrent disease and systemic amyloidosis, on hemodialysis for ESRD. She was treated with various regimens including melphalan, prednisone, VAD, thalidomide, and velcade.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT00222105",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}